CSF amyloid-β 1-38 and 1-42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction

Proteomics - Clinical Applications

Volumn 2, Issue 10-11, 2008, Pages 1548-1556

  Bibl, Mirko ^a   Lewczuk, Piotr ^b   Esselmann, Hermann ^b   Mollenhauer, Brit ^c   Klafki, Hans Wolfgang ^b   Welge, Volker ^c   Wolf, Stefanie ^c   Trenkwalder, Claudia ^c   Otto, Markus ^d   Kornhuber, Johannes ^b   Wiltfang, Jens ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

Alzheimer's disease; Amyloid b peptides; Cerebrospinal fluid; Electrochemiluminescence; Frontotemporal dementia

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; DETERGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE CARRIER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTOTEMPORAL DEMENTIA; HIGH THROUGHPUT SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; WESTERN BLOTTING;

EID: 59849101898     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200800006     Document Type: Article

References (31)

1. Arnold, S. E., Han, L. Y., Clark, C. M., Grossman, M., Trojanowski, J. Q., Quantitative neurohistological features of frontotemporal degeneration. J. Struct. Biol. 2000, 130, 271-279.
2. Bibl, M., Mollenhauer, B., Esselmann, H., Lewczuk, P. et al., CSF amyloid-b-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 2006, 129, 1177-1187.
3. Bibl, M., Mollenhauer, B., Lewczuk, P., Esselmann, H. et al., Validation of amyloid-b peptides in CSF diagnosis of neuro-degenerative dementias. Mol. Psy. 2007, 12, 671-680.
4. Bibl, M., Mollenhauer, B., Wolf, S., Esselmann, H. et al., Reduced CSF carboxyterminally truncated Ab petides in frontotemporal lobe degenerations. J. Neural. Transm. 2007, 114, 621-628.
5. Sjögren, M., Davidsson, P., Tullberg, M., Minthon, L. et al., Both total and phosphorylated tau are increased in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatr. 2001, 70, 624-630.
6. Sjögren, M., Rosgren, L., Minthon, L., Davidson, P. et al., Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 2000, 54, 1960-1964.
7. Riemenschneider, M., Wagenpfeil, S., Diehl, J., Lautenschlager, N. et al., Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration. Neurology 2002, 58, 1622-1628.
8. Hampel, H., Buerger, K., Zinkowski, R., Teipel, S. J. et al., Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer's disease - a comparative study. Arch. Gen. Psychiatr. 2004, 61, 95-102.
9. World Medical Organisation. Declaration of Helsinki. Br. Med. J. 1996, 313, 1448-1449.
10. Bibl, M., Esselmann, H., Otto, M., Lewczuk, P. et al., Cerebrospinal fluid (CSF) amyloid beta (Aβ) peptide patterns in Alzheimer's disease (AD) patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of Aβ peptides. Electrophoresis 2004, 25, 2912-2918.
11. Wiltfang, J., Esselmann, H., Bibl, M., Smirnov, A. et al., Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and patients with chronic neuroinflammation. J. Neurochem. 2002, 81, 481-496.
12. Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C. et al., Improved discrimination of AD-patients using β-amyloid (1-42) and tau levels in CSF. Neurology 1999, 52, 1555-1562.
13. McKhann, G., Drachman, D., Folstein, M., Katzman, R. et al., Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34, 939-944.
14. Neary, D., Snowden, J. S., Gustafson, L., Passant, U. et al., Frontotemporal lobardegeneration. A consensus on clinical diagnostic criteria. Neurology 1998, 51, 1546-1554.
15. Roman, G. C., Tatemichi, T. K., Erkinjutti, T, Cummings, J. L. et al., Vascular dementia: Diagnostic criteria for research studies: Report of the NINDS-AIREN international workshop. Neurology 1993, 43, 243-245.
16. McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K. et al., Consensus guidlines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996, 47, 1113-1124.
17. Gibb, W. R., Lees, A. J., The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 1988, 51, 745-752.
18. Ishikawa, M., Guideline committee for idiopathic normal pressure hydrocephalus, Japanese society of normal pressure hydrocephalus. Neurol. Med. Chir. 2004, 44, 222-223.
19. Litvan, I., Progressive supranuclear palsy and corticobasal degeneration. Baillieres Clin. Neurol. 1997, 6, 167-185.
20. WHO: World Health Organisation. Human transmissible spongiform encephalopathy. Wkly. Epidemiol. Rec. 1998, 73, 361-365.
21. Oslin, D., Aktinsson, R. M., Smith, D. M., Hendrie, H, Alcohol related dementia: Proposed clinical criteria. Int. J. Ger. Psychiatr. 1998, 13, 203-212.
22. Schoonenboom, N. S., Mulder, C, Van Kamp, G. J., Mehta, S. P. et al., Amyloid β 38, 40 and 42 species in cerebrospinal fluid: More of the same? Ann. Neurol. 2005, 58, 139-142.
23. Motter, R., Vigo-Pelfrey, C., Kholodenko, D., Barbour, R. et al., Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 1995, 38, 643-648.
24. Koudinov, A. R., Koudinova, N. V., Kumar, A, Beavis, R. C., Ghiso, J., Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: Association with density lipoproteins. Biochm. Biophys. Res. Commun. 1996, 223, 592-597.
25. Erickson, R. R., Dunning, L. M., Olson, D. A., Cohen, S. J. et al., In cerebrospinal fluid ER chaperones ERp57 and calreticulin bind beta-amyloid. Biochem. Biophys. Res. Commun. 2005, 332, 50-57.
26. Henkel, A. W., Dittrich, P. S., Groemer, T. W., Lemke, E. A. et al., Immune complexes of auto-antibodies against Abeta1-42 peptides patrol cerebrospinal fluid of nonAlzheimer's patients. Mol. Psychiatr. 2007, 12, 601-610.
27. Eckman, E. A., Eckman, C. B., Aβ-degrading enzymes: Modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem. Soc. Trans. 2005, 33, 1101-1105.
28. Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S. Y. et al., Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann. Neurol. 2006, 59, 512-519.
29. 40 CSF concentrations correlate to frontal lobe atrophy in frontotemporal dementia. Neuroreport 2000, 11, 287-290.
30. Dermaut, B., Kumar-Singh, S., Engelborghs, S., Theuns, J. et al., A novel presenilin 1 mutation associated with Pick's disease but not b-amyloid plaques. Ann. Neurol. 2004, 55, 617-626.
31. Lewczuk, P., Esselmann, H., Otto, M., Maler, J. M. et al., Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta 42, Abeta42/ Abeta40 ratio and total tau. Neurobiol. Aging 2004, 25, 273-281.